About Dr. Fein
Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.
Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment, to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.
Dr. Fein’s popular and influential Drug Channels blog is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, Fortune, Drug Benefit News, and many others.
Dr. Fein also is a popular speaker. He inspires his audiences to think strategically with content-rich and entertaining keynote presentations.
Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife and their two children.
Dr. Fein in the News
Gottlieb Tapped for FDA Commissioner Spot Drug Topics
FDA and CMS nominations move ahead under the Trumpcare fog Pharmaceutical Commerce
Express Scripts, Pharmacies Collide Over Network Cuts Bloomberg BNA
Md. drug-pricing measures misguided The Daily Record
Million-dollar drug keeps local woman alive Dayton Daily News
Considering Specialty Pharmacy? Make Your Move Drug Topics
Why PBMs Lead in Prescription Revenue Growth Drug Topics
Specialty drugs shake up field of Rx players Chain Drug Review
CoverMyMeds' sale for $1.1 billion touted as 'seminal' for central Ohio Columbus Dispatch
Specialty Pharmacies Say Benefit Managers Are Squeezing Them Out The New York Times
Walgreens, Rite-Aid Find Unlikely Buyer for 865 Stores The Wall Street Journal